Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
Name:
35393425.pdf
Size:
559.8Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Telli, M. L.Tolaney, S. M.
Shapiro, G. I.
Middleton, M.
Lord, S. R.
Arkenau, H. T.
Tutt, A.
Abramson, V.
Dean, Emma J
Haddad, T. C.
Wesolowski, R.
Ferrer-Playan, J.
Goddemeier, T.
Grombacher, T.
Dong, J.
Fleuranceau-Morel, P.
Diaz-Padilla, I.
Plummer, R.
Affiliation
Stanford University School of Medicine, Stanford, CA, USAIssue Date
2022
Metadata
Show full item recordAbstract
Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on the recommended phase 2 dose of the combination of the ataxia-telangiectasia and Rad3-related (ATR) inhibitor berzosertib and cisplatin observed in patients with advanced solid tumors, including TNBC. Forty-seven patients aged ≥18 years with advanced TNBC received cisplatin (75 mg/m2; day 1) and berzosertib (140 mg/m2; days 2 and 9), in 21-day cycles. Berzosertib was well tolerated, with a similar toxicity profile to that reported previously for this combination. The overall response rate (90% confidence interval) was 23.4% (13.7, 35.8). No relevant associations were observed between response and gene alterations. Further studies combining ATR inhibitors with platinum compounds may be warranted in highly selected patient populations.Citation
Telli ML, Tolaney SM, Shapiro GI, Middleton M, Lord SR, Arkenau HT, et al. Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. Vol. 8, npj Breast Cancer. Springer Science and Business Media LLC; 2022.Journal
NPJ Breast CancerDOI
10.1038/s41523-022-00406-0PubMed ID
35393425Additional Links
https://dx.doi.org/10.1038/s41523-022-00406-0Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41523-022-00406-0
Scopus Count
Collections
Related articles
- Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
- Authors: Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R, Yap TA
- Issue date: 2021 Aug
- Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
- Authors: Terranova N, Jansen M, Falk M, Hendriks BS
- Issue date: 2021 Feb
- Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
- Authors: Rinnerthaler G, Gampenrieder SP, Petzer A, Burgstaller S, Fuchs D, Rossmann D, Balic M, Egle D, Rumpold H, Singer CF, Bartsch R, Petru E, Melchardt T, Ulmer H, Mlineritsch B, Greil R
- Issue date: 2018 Nov 6
- Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.
- Authors: Talele S, Zhang W, Burgenske DM, Kim M, Mohammad AS, Dragojevic S, Gupta SK, Bindra RS, Sarkaria JN, Elmquist WF
- Issue date: 2021 Dec
- Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
- Authors: Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM
- Issue date: 2016 Jun 15